Cyclooxygenase-2 inhibitors and myocardial infarction.
Goldstein
Mark R
MR
D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011464:Epoprostenol / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000209:etiology*; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013931:Thromboxanes / Q000378:metabolism
D016861:Cyclooxygenase Inhibitors; D013931:Thromboxanes; D011464:Epoprostenol